PATENT CLAIM ANALYSIS

Application Number: 16148055
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["424", "258100"]

Abstract:
A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.

Claim (Index 20):
A live genetically engineered bacterium, comprising:\n a chromosomally-integrated genetically engineered DNA construct, having a promoter sequence and encoding a fusion comprising a bacterial secretion peptide portion and an immunogenic polypeptide portion; at least one phage repressor; deletions in bacteria phage or prophage elements with respect to a wild type bacterium from which the live genetically engineered bacterium is derived; a secretion mechanism which interacts with at least the bacterial secretion peptide portion, to cause a secretion of the fusion peptide from the live genetically engineered bacterium; and at least one genetic virulence attenuating mutation with respect to a wild type bacterium from which the live genetically engineered bacterium is derived, wherein the live genetically engineered bacterium is adapted to persist in a gut of a human or animal after administration to cause a therapeutic or preventative vaccination response to a virus or organism which is associated with the immunogenic polypeptide portion.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 97.0
- Lexical Diversity: 2.13636
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15131083', '13369333', '13892380', '15243904', '12560947']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8630486042909548
- 35 USC 102 Novelty (BERT): 0.6857609551403658
- Combined Prediction Score: 0.8453198393758958
- Mean Citation Score: 662.1604659999998
- Max Citation Score: 778.4626
- Similarity Product: 689.7259197512984

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test